Welcome to our dedicated page for Grifols S A news (Ticker: GRFS), a resource for investors and traders seeking the latest updates and insights on Grifols S A stock.
News about Grifols, S.A. (GRFS) centers on its role as a global healthcare company focused on plasma-derived medicines, transfusion medicine and biopharmaceutical innovation. Founded in Barcelona in 1909 and active in more than 110 countries, Grifols regularly reports developments that matter to investors, healthcare professionals and patients.
Company news often highlights regulatory milestones for its plasma-based therapies and immunoglobulin products. Recent announcements include U.S. Food and Drug Administration (FDA) decisions on the subcutaneous immunoglobulin XEMBIFY, a fibrin sealant for surgical bleeding, and Biotest’s intravenous immunoglobulin Yimmugo. Updates on partnerships, such as collaborations with BARDA on ocular surface immunoglobulin eye drops and with The Michael J. Fox Foundation on Parkinson’s disease biomarker research, also feature prominently.
From a corporate perspective, Grifols’ news flow includes quarterly and half‑year financial results, progress on its Value Creation Plan, changes in leverage and liquidity, and dividend decisions. Filings and press releases describe revenue growth led by the Biopharma segment, trends in immunoglobulin, albumin and Alpha‑1 franchises, and performance of its Diagnostic business. Governance-related items, including amendments to Board regulations and commentary from shareholders such as Mason Capital Management, appear in communications and can influence market perception.
On this page, readers can follow earnings releases, product and pipeline updates, strategic collaborations, governance developments and other material announcements related to Grifols’ operations and capital markets activity. For investors tracking GRFS, this news stream provides context on how the company’s plasma-derived medicines, diagnostics and research initiatives evolve over time.
Grifols has completed the sale of a 20% equity stake in Shanghai RAAS (SRAAS) to Haier Group for RMB 12.5 billion (EUR 1.6 billion). The strategic alliance aims to enhance China's healthcare system through synergies between Grifols' plasma and diagnostic expertise and Haier's healthcare solutions portfolio. Grifols retains a 6.58% stake in SRAAS and a seat on the Board of Directors. The exclusive albumin distribution agreement between Grifols and SRAAS is extended for 10 years, with an option to prolong it to 2044. Proceeds from the sale will be used by Grifols to reduce debt. The collaboration seeks to capitalize on China's growing demand for albumin and expand their footprint in life sciences, clinical medicine, and biotechnology.
The transaction has received regulatory approvals and compliance confirmation from the Shenzhen Stock Exchange. Grifols and SRAAS have worked together for four years, during which the Chinese hemoderivatives market has seen double-digit growth.
Grifols announced that its subsidiary Biotest has received FDA approval for Yimmugo®, an innovative intravenous immunoglobulin (Ig) to treat primary immunodeficiencies (PID). This approval marks Yimmugo as the first U.S.-approved medicine in Biotest’s portfolio, produced at their FDA-certified facility in Germany. Already approved in Europe, Yimmugo’s U.S. launch is expected in the latter half of 2024. The approval is anticipated to bolster Grifols' revenue and support its growth strategy. Additionally, Biotest has two more plasma proteins in late-stage development aimed at U.S. and other markets.
FAQ
What is the current stock price of Grifols S A (GRFS)?
What is the market cap of Grifols S A (GRFS)?
